Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22

Journal of Analytical Toxicology

Volumn 38, Issue 8, 2014, Pages 559-562

  Behonick, George ^a   Shanks, Kevin G ^a   Firchau, Dennis J ^b   Mathur, Gagan ^b   Lynch, Charles F ^b   Nashelsky, Marcus ^b   Jaskierny, David J ^c   Meroueh, Chady ^d  

^a AIT Laboratories   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c Physicians Laboratory Services   (United States)

^d Mercy Medical Center North Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5F PB 22; ACETIC ACID ETHYL ESTER; ALCOHOL; AMIODARONE; CAFFEINE; CANNABINOID DERIVATIVE; CANNABIS; HEXANE; UNCLASSIFIED DRUG; CANNABINOID;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALCOHOL BLOOD LEVEL; ARTICLE; AUTOPSY; BLOOD SAMPLING; CASE REPORT; CAUSE OF DEATH; DRUG BLOOD LEVEL; DRUG INTOXICATION; ELECTROSPRAY MASS SPECTROMETRY; FULMINANT HEPATIC FAILURE; GRANULOMATOUS INFLAMMATION; HEART ARREST; HUMAN; ISCHEMIA; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LUNG EDEMA; MALE; PH; QUANTITATIVE ANALYSIS; RESPIRATORY FAILURE; SUDDEN DEATH; TANDEM MASS SPECTROMETRY; BLOOD; EVALUATION STUDY; FEMALE; FORENSIC TOXICOLOGY; LIMIT OF DETECTION; PROCEDURES; REPRODUCIBILITY; SPECIMEN HANDLING; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOPSY; CANNABINOIDS; CHROMATOGRAPHY, LIQUID; EVALUATION STUDIES AS TOPIC; FEMALE; FORENSIC TOXICOLOGY; HUMANS; LIMIT OF DETECTION; LIQUID-LIQUID EXTRACTION; MALE; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; YOUNG ADULT;

EID: 84984991373     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bku048     Document Type: Article

References (19)

1. Penn, H.J., Langman, L.J., Unold, D., Shields, J., Nichols, J.H. (2011) Detection of synthetic cannabinoids in herbal incense products. Clinical Biochemistry, 44, 1163-1165.
2. Logan, B.K., Reinhold, L.E., Xu, A., Diamond, F.X. (2012) Identification of synthetic cannabinoids in herbal incense blends in the United States. Journal of Forensic Sciences, 57, 1168-1180.
3. Shanks, K.G., Dahn, T., Behonick, G., Terrell, A. (2012) Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. Journal of Analytical Toxicology, 36, 360-371.
4. Shanks, K.G., Behonick, G.S., Dahn, T., Terrell, A. (2013) Identification of novel third-generation synthetic cannabinoids in products by ultra-performance liquid chromatography and time-of-flight mass spectrometry. Journal of Analytical Toxicology, 37, 517-525.
5. Presley, B.C., Jansen-Varnum, S.A., Logan, B.K. (2013) Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings. Forensic Science Review, 25, 27-46.
6. Tofighi, B., Lee, J.D. (2012) Internet highs-seizures after consumption of synthetic cannabinoids purchased online. Journal of Addiction Medicine, 6, 240-241.
7. Young, A.C., Schwarz, E., Medina, G., Obafemi, A., Feng, S.Y., Kane, C. et al. (2011) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. The American Journal of Emergency Medicine, 30, 1320.e5-1320.e7.
8. Lapoint, J., James, L.P., Moran, C.L., Nelson, L.S., Hoffman, R.S., Moran, J.H. (2011) Severe toxicity following synthetic cannabinoid ingestion. Clinical Toxicology, 49, 760-764.
9. Thornton, S.L.,Wood, C., Friesen, M.W., Gerona, R.R. (2013) Synthetic cannabinoid use associated with acute kidney injury. Clinical Toxicology, 51, 189-190.
10. Centers for Disease Control and Prevention (CDC). (2013) Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morbidity and Mortality Weekly Report, 62, 93-98.
11. Centers for Disease Control and Prevention (CDC). (2013) Notes from the field: severe illness associated with synthetic cannabinoid use-Brunswick, Georgia, 2013. MMWR Morbidity and Mortality Weekly Report, 62, 939.
12. Centers for Disease Control and Prevention (CDC). (2013) Notes from the field: severe illness associated with reported use of synthetic marijuana -Colorado, August-September 2013. MMWR Morbidity and Mortality Weekly Report, 62, 1016-1017.
13. Shanks, K.G., Dahn, T., Terrell, A.R. (2012) Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. Journal of Analytical Toxicology, 36, 145-152.
14. Kronstrand, R., Roman, M., Andersson, M., Eklund, A. (2013) Toxicological findings of synthetic cannabinoids in recreational users. Journal of Analytical Toxicology, 37, 534-541.
15. Yeakel, J.K., Logan, B.K. (2013) Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. Journal of Analytical Toxicology, 37, 547-551.
16. Gurney, S.M.R., Scott, K.S., Kacinko, S.L., Presley, B.C., Logan, B.K. (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Science Review, 26, 53-78.
17. Drug Enforcement Administration. (2013) Establishment of drug codes for 26 substances. Federal Register, 78(3), 664-666.
18. Drug Enforcement Administration, Department of Justice. (2013) Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final rule. Federal Register, 78, 28735-28739.
19. Drug Enforcement Administration, Department of Justice. (2014) Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. Federal Register, 79, 7577-7582.